University of Perugia

About: University of Perugia is a education organization based out in Perugia, Umbria, Italy. It is known for research contribution in the topics: Population & Large Hadron Collider. The organization has 13365 authors who have published 39516 publications receiving 1265601 citations. The organization is also known as: Universitá degli Studi di Perugia & Universita degli Studi di Perugia.

Constraints on sub-GeV dark matter-electron scattering from the DarkSide-50 experiment

Abstract: We present new constraints on sub-GeV dark-matter particles scattering off electrons based on 6780.0 kg d of data collected with the DarkSide-50 dual-phase argon time projection chamber. This analysis uses electroluminescence signals due to ionized electrons extracted from the liquid argon target. The detector has a very high trigger probability for these signals, allowing for an analysis threshold of three extracted electrons, or approximately 0.05 keVee. We calculate the expected recoil spectra for dark matter-electron scattering in argon and, under the assumption of momentum-independent scattering, improve upon existing limits from XENON10 for dark-matter particles with masses between 30 and 100 MeV/c^{2}.

Towards the sustainable discovery and development of new antibiotics

Abstract: An ever-increasing demand for novel antimicrobials to treat life-threatening infections caused by the global spread of multidrug-resistant bacterial pathogens stands in stark contrast to the current level of investment in their development, particularly in the fields of natural-product-derived and synthetic small molecules. New agents displaying innovative chemistry and modes of action are desperately needed worldwide to tackle the public health menace posed by antimicrobial resistance. Here, our consortium presents a strategic blueprint to substantially improve our ability to discover and develop new antibiotics. We propose both short-term and long-term solutions to overcome the most urgent limitations in the various sectors of research and funding, aiming to bridge the gap between academic, industrial and political stakeholders, and to unite interdisciplinary expertise in order to efficiently fuel the translational pipeline for the benefit of future generations.

Observation of a Charged (D(D)over-bar*)(+/-) Mass Peak in e(+)e(-) -> pi D(D)over-bar* at root s=4.26 GeV

Abstract: We report on a study of the process e(+)e(-) -> pi(+/-) (D (D) over bar*)(-/+) at root s = 4.26 GeV using a 525 pb(-1) data sample collected with the BESIII detector at the BEPCII storage ring. A distinct charged structure is observed in the (D (D) over bar*)(-/+) invariant mass distribution. When fitted to a mass- dependent- width Breit- Wigner line shape, the pole mass and width are determined to be M-pole (3883: 9 +/- 1.5 (stat) +/- 4.2 dsyst__ MeV= c(2) and Gamma(pole) = (24: 8 +/- 3.3 (stat) +/- 11: 0 (syst)) MeV. The mass and width of the structure, which we refer to as Z(c)(3885), are 2 sigma and 1 sigma, respectively, below those of the Z(c)(3900) -> pi(+/-) J/psi peak observed by BESIII and Belle in pi(+)pi(-) J/psi final states produced at the same center- of- mass energy. The angular distribution of the pi Z(c)(3885) system favors a J(P) = J(P) = 1(+) quantum number assignment for the structure and disfavors 1(-) or 0(-). The Born cross section times the (D (D) over bar*) branching fraction of the Z(c)(3885) is measured to be sigma(e(+)e(-) -> pi(+/-)Z(c)(3885)(-/+)) x B(Z(c)(3885)-/+ -> (D (D) over bar*)(-/+) = (83.5 +/- 6.6 (stat) +/- 22.0 (syst)) pb. Assuming the Z(c)(3885) -> (D (D) over bar*)(-/+) signal reported here and the Z(c)(3900) -> pi J/psi signal are from the same source, the partial width ratio (Gamma(Z(c)(3885) -> D (D) over bar*)/Gamma(Z(c)(3900) -> pi J/psi)) = 6.2 +/- 1.1 (stat) +/- 2.7 (syst) is determined.

Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015

Abstract: This is the sixth special report that the European Society for Blood and Marrow Transplantation regularly publishes on the current practice and indications for haematopoietic SCT for haematological diseases, solid tumours and immune disorders in Europe. Major changes have occurred in the field of haematopoietic SCT over the last years. Cord blood units as well as haploidentical donors have been increasingly used as stem cell sources for allo-SCT, thus, augmenting the possibility of finding a suitable donor for a patient. Continuous refinement of conditioning strategies has also expanded not only the number of potential indications but also has permitted consideration of older patients or those with co-morbidity for a transplant. There is accumulating evidence of the role of haematopoietic SCT in non-haematological disorders such as autoimmune diseases. On the other hand, the advent of new drugs and very effective targeted therapy has challenged the role of SCT in some instances or at least, modified its position in the treatment armamentarium of a given patient. An updated report with revised tables and operating definitions is presented.